<DOC>
	<DOCNO>NCT01976923</DOCNO>
	<brief_summary>The purpose study assess efficacy pre-operative intravitreal bevacizumab ( IVB ) ( Genentech , South San Francisco CA ) improve visual acuity , reduce operative time , complication , intra-operative post-operative hemorrhage follow small gauge par plana vitrectomy ( PPV ) ( 23-gauge , 25-gauge 27-gauge ) compare small gauge PPV ( 23-gauge , 25-gauge 27-gauge ) alone eyes tractional retinal detachment ( TRD ) secondary proliferative diabetic retinopathy ( PDR ) . Hypothesis : Preoperative IVB may beneficial membrane dissection diabetic tractional retinal detachment minimally invasive vitreoretinal surgery ( 23-gauge transconjunctival sutureless vitrectomy [ TSV ] ) . In addition , post-operative rebleeding may decrease .</brief_summary>
	<brief_title>Pre-Operative Intravitreal Bevacizumab Tractional Retinal Detachment Secondary Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description>This prospective , randomize , active-controlled study 374 eye patient diagnosis TRD secondary PDR . Participants screen eligibility . Eligible patient examine baseline determine ocular condition randomize 2 arm . Patients randomize 3:1 ratio study arm . 1 . Control arm : PPV without pre-operative bevacizumab ( Sham injection ) . 2 . Study arm : Pre-operative bevacizumab ( 3-5 day ) PPV . In study arm , intravitreal bevacizumab injection dose 1.25 Âµg/0.05 mL schedule 3 5 day minimally invasive vitreoretinal surgery ( MIVS ) . The purpose current study determine effectiveness safety intravitreal injection 1.25 mg bevacizumab pre-operative adjunct PPV eye TRD secondary PDR .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Dissociative Disorders</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temazepam</mesh_term>
	<criteria>1 . Age &gt; = 18 year proliferative diabetic retinopathy ( PDR ) tractional retinal detachment ( TRD ) threaten involve fovea . 2 . Diagnosis diabetes mellitus ( type 1 type 2 ) 3 . At least one eye meet study eye criterion 4 . One eye per patient include 5 . Able willing provide inform consent prior studyrelated procedure 6 . Best correct visual acuity 20/40 less 7 . Willing able comply clinic visit studyrelated procedure 8 . U.S. patient require Health Insurance Portability Accountability Act ( HIPAA ) authorization ; country , applicable accord national law Ocular Exclusion Criteria The following exclusion apply study eye ( i.e. , may present nonstudy eye ) : 1 . TRD consider due cause diabetes . 2 . An ocular condition present , opinion investigator , visual acuity loss would improve resolution TRD ( e.g. , foveal atrophy , pigment abnormality , dense subfoveal hard exudate , nonretinal condition , optic atrophy ) . 3 . An ocular condition present ( diabetes ) , opinion investigator , might affect retinal status alter visual acuity course study ( e.g. , retinal vein occlusion , uveitis ocular inflammatory disease , glaucoma , etc . ) 4 . History treatment diabetic macular edema diabetic retinopathy time past 4 month antivascular endothelial growth factor ( VEGF ) drug . 5 . History major ocular surgery ( include vitrectomy , cataract extraction , scleral buckle , intraocular surgery , etc . ) within prior 4 month randomization . 6 . History neodymiumdoped yttrium aluminium garnet ( YAG ) capsulotomy perform within 2 month prior randomization . 7 . Intraocular pressure &gt; = 25 mmHg . 8 . Exam evidence external ocular infection , include conjunctivitis , chalazion , significant blepharitis 9 . An ocular condition present ( diabetes ) , opinion investigator , might affect retinal status include hypertension , cardiovascular disease , glycemic control . Systemic Exclusion Criteria A participant eligible follow exclusion criterion present : 1 . Significant renal disease , define history chronic renal failure require dialysis kidney transplant . 2 . A condition , opinion investigator , would preclude participation study ( e.g. , unstable medical status include hypertension , cardiovascular disease , glycemic control ) . 3 . Participation investigational trial within 30 day randomization involve treatment drug receive regulatory approval time study entry . 4 . Known allergy component study drug . 5 . Blood pressure &gt; 180/110 mmHg ( systolic 180 diastolic 110 ) . 6 . Major surgery within 28 day prior randomization major surgery plan next 6 month . 7 . Myocardial infarction , cardiac event require hospitalization , stroke , transient ischemic attack , treatment acute congestive heart failure within 4 month prior randomization . 8 . Systemic antiVEGF VEGF treatment within 4 month prior randomization . 9 . For woman childbearing potential : pregnant lactate intend become pregnant within next 12 month . 10 . Participant expect move area clinical center area cover another clinical center first 12 month study . 11 . Participation investigational trial within 30 day randomization involve treatment drug receive regulatory approval time study entry . 12 . Known allergy component study drug . 13 . Blood pressure &gt; 180/110 mmHg ( systolic 180 diastolic 110 ) . 14 . Major surgery within 28 day prior randomization major surgery plan next 6 month . 15 . Myocardial infarction , cardiac event require hospitalization , stroke , transient ischemic attack , treatment acute congestive heart failure within 4 month prior randomization . 16 . Systemic antiVEGF VEGF treatment within 4 month prior randomization . 17 . For woman childbearing potential : pregnant lactate intend become pregnant within next 12 month . 18 . Participant expect move area clinical center area cover another clinical center first 12 month study . 19 . History blood disease associate abnormal coagulation . 20 . Anticoagulant therapy ( warfarin heparin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Intravitreal Bevacizumab</keyword>
	<keyword>Tractional Retinal Detachment</keyword>
	<keyword>Proliferative Diabetic Retinopathy</keyword>
	<keyword>Small gauge par plana vitrectomy</keyword>
	<keyword>Intraoperative bleeding</keyword>
	<keyword>Post-operative vitreous hemorrhage</keyword>
	<keyword>Visual acuity</keyword>
</DOC>